Overview

A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug

Status:
Withdrawn

Trial end date:
2017-10-26

Target enrollment:

Participant gender:

Summary

A pediatric drug study to determine the long-term safety and tolerability in children and adolescents (4-17 years in age) taking the drug (elsicarbazepine acetate)

Phase:

Phase 3

Details

Lead Sponsor:

Sunovion

Treatments:

Eslicarbazepine acetate